Literature DB >> 17323313

Sample size calculation for the Power Model for dose proportionality studies.

Venkat S Sethuraman1, Sergei Leonov, Lisa Squassante, Toni R Mitchell, Michael D Hale.   

Abstract

There are several approaches to assess or demonstrate pharmacokinetic dose proportionality. One statistical method is the traditional ANOVA model, where dose proportionality is evaluated using the bioequivalence limits. A more informative method is the mixed effects Power Model, where dose proportionality is assessed using a decision rule for the estimated slope. Here we propose analytical derivations of sample sizes for various designs (including crossover, incomplete block and parallel group designs) to be analysed according to the Power Model.

Mesh:

Year:  2007        PMID: 17323313     DOI: 10.1002/pst.241

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  3 in total

1.  Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Authors:  Peter L Anderson; Albert Y Liu; Jose R Castillo-Mancilla; Edward M Gardner; Sharon M Seifert; Cricket McHugh; Theresa Wagner; Kayla Campbell; Mary Morrow; Mustafa Ibrahim; Susan Buchbinder; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.

Authors:  Skyler Peterson; Mustafa Ibrahim; Peter L Anderson; Camille M Moore; Samantha MaWhinney
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-19       Impact factor: 2.745

3.  Pharmacokinetics, Tissue Distribution, and Excretion Characteristics of a Radix Polygoni Multiflori Extract in Rats.

Authors:  Wenhao Cheng; Siyang Wu; Zheng Yuan; Weiyu Hu; Xin Yu; Nianxin Kang; Qiutao Wang; Mingying Zhu; Kexin Xia; Wei Yang; Chen Kang; Shuofeng Zhang; Yingfei Li
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.